{"DataElement":{"publicId":"7801141","version":"1","preferredName":"Patient AJCC Cancer Staging Manual 8th Edition Melanoma T Category Clinical Trial Eligibility Criteria Staging Code","preferredDefinition":"The code that represents the patient's T stage for melanoma according to the American Joint Committee on Cancer Staging Manual, Edition 8, as outlined in the eligibility criteria of the protocol","longName":"HISTREPORTSTAGEDISPLAY","context":"SWOG","contextVersion":"1","DataElementConcept":{"publicId":"7801131","version":"1","preferredName":"Patient AJCC Cancer Staging Manual 8th Edition Melanoma T Category Clinical Trial Eligibility Criteria","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._The 8th edition of the criteria developed by the American Joint Committee on Cancer (AJCC), implemented in 2018, used for the classification and staging of neoplastic diseases._A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain._One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion)._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"2233604v1.0:7802143v1.0","context":"SWOG","contextVersion":"1","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7802143","version":"1","preferredName":"AJCC Cancer Staging Manual 8th Edition Melanoma T Category Clinical Trial Eligibility Criteria","preferredDefinition":"The 8th edition of the criteria developed by the American Joint Committee on Cancer (AJCC), implemented in 2018, used for the classification and staging of neoplastic diseases.:A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.:One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"C146985:C3224:C25728:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AJCC Cancer Staging Manual 8th Edition","conceptCode":"C146985","definition":"The 8th edition of the criteria developed by the American Joint Committee on Cancer (AJCC), implemented in 2018, used for the classification and staging of neoplastic diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Melanoma","conceptCode":"C3224","definition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"T Category","conceptCode":"C25728","definition":"One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFE550A6-235C-23D0-E053-4EBD850AE9B2","latestVersionIndicator":"Yes","beginDate":"2021-11-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-11-03","modifiedBy":"ONEDATA","dateModified":"2021-11-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF6B67FB-AEB5-252D-E053-4EBD850A3EDA","latestVersionIndicator":"Yes","beginDate":"2021-10-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-28","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeDescription":"12/9/21 TL released AI. 10/28/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7801134","version":"1","preferredName":"Melanoma Staging Code","preferredDefinition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain._Performing exams and tests to learn the extent of the cancer within the body, especially whether the disease has spread from the original site to other parts of the body. It is important to know the stage of the disease in order to plan the best treatment._A symbol or combination of symbols which is assigned to the members of a collection.","longName":"7801134v1.0","context":"SWOG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"4","valueDescription":"4 = Stage IIC (pT4b)","ValueMeaning":{"publicId":"7801135","version":"1","preferredName":"4 = Stage IIC (pT4b)","longName":"7801135","preferredDefinition":"4 = Stage IIC (pT4b)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF6B6FDD-6863-0D4E-E053-4EBD850A8723","latestVersionIndicator":"Yes","beginDate":"2021-10-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-28","modifiedBy":"ONEDATA","dateModified":"2021-10-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CF6B6FDD-687C-0D4E-E053-4EBD850A8723","beginDate":"2021-10-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-28","modifiedBy":"ONEDATA","dateModified":"2021-10-28","deletedIndicator":"No"},{"value":"3","valueDescription":"3 = Stage IIB (pT4a)","ValueMeaning":{"publicId":"7801136","version":"1","preferredName":"3 = Stage IIB (pT4a)","longName":"7801136","preferredDefinition":"3 = Stage IIB (pT4a)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF6B6FDD-6886-0D4E-E053-4EBD850A8723","latestVersionIndicator":"Yes","beginDate":"2021-10-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-28","modifiedBy":"ONEDATA","dateModified":"2021-10-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CF6B6FDD-689F-0D4E-E053-4EBD850A8723","beginDate":"2021-10-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-28","modifiedBy":"ONEDATA","dateModified":"2021-10-28","deletedIndicator":"No"},{"value":"2","valueDescription":"2 = Stage IIB (pT3b)","ValueMeaning":{"publicId":"7801137","version":"1","preferredName":"2 = Stage IIB (pT3b)","longName":"7801137","preferredDefinition":"2 = Stage IIB (pT3b)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF6B6FDD-68A9-0D4E-E053-4EBD850A8723","latestVersionIndicator":"Yes","beginDate":"2021-10-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-28","modifiedBy":"ONEDATA","dateModified":"2021-10-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CF6B6FDD-68C2-0D4E-E053-4EBD850A8723","beginDate":"2021-10-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-28","modifiedBy":"ONEDATA","dateModified":"2021-10-28","deletedIndicator":"No"},{"value":"1","valueDescription":"1 = Stage IIA (pT3a)","ValueMeaning":{"publicId":"7801138","version":"1","preferredName":"1 = Stage IIA (pT3a)","longName":"7801138","preferredDefinition":"1 = Stage IIA (pT3a)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF6B6FDD-68CC-0D4E-E053-4EBD850A8723","latestVersionIndicator":"Yes","beginDate":"2021-10-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-28","modifiedBy":"ONEDATA","dateModified":"2021-10-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CF6B6FDD-68E5-0D4E-E053-4EBD850A8723","beginDate":"2021-10-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-28","modifiedBy":"ONEDATA","dateModified":"2021-10-28","deletedIndicator":"No"},{"value":"0","valueDescription":"0 = Stage IIA (pT2b)","ValueMeaning":{"publicId":"7801139","version":"1","preferredName":"0 = Stage IIA (pT2b)","longName":"7801139","preferredDefinition":"0 = Stage IIA (pT2b)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF6B6FDD-68EF-0D4E-E053-4EBD850A8723","latestVersionIndicator":"Yes","beginDate":"2021-10-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-28","modifiedBy":"ONEDATA","dateModified":"2021-10-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CF6B6FDD-6908-0D4E-E053-4EBD850A8723","beginDate":"2021-10-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-28","modifiedBy":"ONEDATA","dateModified":"2021-10-28","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7801100","version":"1","preferredName":"Melanoma Staging Code","preferredDefinition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.:Performing exams and tests to learn the extent of the cancer within the body, especially whether the disease has spread from the original site to other parts of the body. It is important to know the stage of the disease in order to plan the best treatment.:A symbol or combination of symbols which is assigned to the members of a collection.","longName":"C3224:C15608:C25162","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melanoma","conceptCode":"C3224","definition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Staging","conceptCode":"C15608","definition":"The process of defining at what point in the natural history of a malignant disease a patient is when a diagnosis is made.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF5A5267-1B88-0314-E053-4EBD850A606F","latestVersionIndicator":"Yes","beginDate":"2021-10-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-27","modifiedBy":"ONEDATA","dateModified":"2021-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF6B6FDD-684C-0D4E-E053-4EBD850A8723","latestVersionIndicator":"Yes","beginDate":"2021-10-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-28","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeDescription":"12/9/21 TL released AI. 10/27/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"AJCC 8th edition staging - Pl","type":"Preferred Question Text","description":"AJCC 8th edition staging - Please select the T stage at the time of randomization","url":null,"context":"SWOG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF6B883E-BB01-21FE-E053-4EBD850A2AF8","latestVersionIndicator":"Yes","beginDate":"2021-10-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-28","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeDescription":"12/9/21 TL released AI. S2015 Enrollment Question","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}